Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases

Genes Chromosomes and Cancer

Volumn 38, Issue 3, 2003, Pages 234-239

  Smadja, Nicole Véronique ^a   Leroux, Dominique ^b   Soulier, Jean ^c   Dumont, Sylvie ^a   Arnould, Catherine ^a   Taviaux, Sylvie ^d   Taillemite, Jean Louis ^a   Bastard, Christian ^d  

^a HÔPITAL SAINT ANTOINE   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d CENTRE HENRI BECQUEREL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN;

ADULT; ARTICLE; CHROMOSOME 14Q; CHROMOSOME ABERRATION; CHROMOSOME NUMBER; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; KARYOTYPE; MALE; METAPHASE; MULTIPLE MYELOMA; PRIORITY JOURNAL; RELIABILITY;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 14; CYTOGENETIC ANALYSIS; DIPLOIDY; FEMALE; HUMANS; KARYOTYPING; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TRANSLOCATION, GENETIC; TRISOMY;

EID: 0141993685     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.10275     Document Type: Article

References (22)

1. Avet-Loiseau H, Li JY, Facon T, Brigaudeau C, Morineau N, Maloisel F, Rapp MJ, Talmant P, Trimoreau F, Jaccard A, Harousseau JL, Bataille R. 1998. High incidence of translocations t(11; 14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 58:5640-5645.
2. Avet-Loiseau H, Brigaudeau C, Morineau N, Talmant P, Laï JL, Daviet A, Li JY, Praloran V, Rapp MJ, Harousseau JL, Facon T, Bataille R. 1999. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer 24:9-15.
3. Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, Minvielle S, Bataille R. for the Intergroupe Francophone du Myélome. 2002. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 99:2185-2191.
4. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM. 1996. Promiscuous translocations into immunoglogulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA 93:13931-13936.
5. Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM, Bergsagel PL. 1997. Frequent translocation t(4;14)(p16.3;q32) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16:260-265.
6. Chesi M, Bergsagel PL, Shonukan OO, Martelli ML, Brents LA, Chen T, Schröck E, Ried T, Kuehl WM. 1998. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 91:4457-4463.
7. Durie BGM, Salmon SE. 1975. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842-854.
8. Finelli P, Fabris S, Zagano S, Baldini L, Intini D, Nobili L, Lombardi L, Maiolo T, Neri A. 1999. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization. Blood 94:724-732.
9. Fonseca R, Oken MM, Greipp PR, on behalf of the Eastern Cooperative Oncology Group Myeloma Group. 2001. The t(4; 14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood 98:1271-1272.
10. Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Hoyer JD, Harrington D, Kay NE, Van Ness B, Griep P. 2002. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 99:3735-3741.
11. Hallek M, Bergsagel PL, Anderson KC. 1998. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91:3-21.
12. Ho PJ, Brown RD, Pelka GJ, Basten A, Gibson J, Joshua DE. 2001. Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival. Blood 97:490-495.
13. Ida S, Rao PH, Butler M, Corradini P, Boccadoro M, Klein B, Chaganti RSK, Dalla-Favera R. 1997. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 17:226-230.
14. Mitelman F, editor. 1995. ISCN: an international system for human cyotgenetic nomenclature. Basel: S. Karger.
15. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL, Bataille R, Avet-Loiseau H, for the Intergroupe Francophone du Myélome. 2002. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 100:1579-1583.
16. Nishida K, Tamura A, Nakazawa N, Ueda Y, Abe T, Matsuda F, Kashima K, Taniwaki M. 1997. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 90:526-534.
17. Pratt G, Fenton AL, Davies FE, Rawstron AC, Richards SJ, Collins JE, Owen RG, Jack AS, Smith GM, Morgan GJ. 2001. Insertional events as well as translocations may arise during aberrant immunoglobulin switch recombination in a patient with multiple myeloma. Br J Haematol 112:388-391.
18. Rao PH, Cigudosa JC, Ning Y, Calasanz MJ, Lida S, Tagawa S, Michaeli J, Klein B, Dalla-Favera R, Jhanwar SC, Ried T, Chaganti RSK. 1998. Multicolor spectral karyotyping identifies new recurrent breakpoints and translocations in multiple myeloma. Blood 92:1743-1748.
19. Richelda R, Ronchetti D, Baldini L, Cro L, Viggiano L, Marzella R, Rocchi M, Otsuki T, Lombardi L, Maiolo AT, Neri A. 1997. A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 90:4062-4070.
20. Smadja NV, Louvet C, Isnard F, Dutel JL, Grange MJ, Varette C, Krulik M. 1995. Cytogenetic study in multiple myeloma at diagnosis: comparison of two techniques. Br J Haematol 90:619-624.
21. Smadja NV, Fruchart C, Isnard F, Louvet C, Dutel JL, Cheron N, Grange MJ, Monconduit M, Bastard C. 1998. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia 12:960-969.
22. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C, on behalf of the groupe Français de Cytogénétique Hématologique. 2001. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98:2229-2238.